# Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT02095834** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Bendamustine Hydrochloride
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02095834
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-24
- **Primary completion:** 2021-01-07
- **Final completion:** 2021-01-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095834, "Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02095834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*